首页 > 最新文献

Chinese medical journal pulmonary and critical care medicine最新文献

英文 中文
Overcoming EGFR-TKI resistance by targeting the tumor microenvironment 通过靶向肿瘤微环境克服表皮生长因子受体-TKI 抗药性
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.08.002
Jinsong Zhang , Natalie Vokes , Man Li , Jiachen Xu , Hua Bai , Jie Wang , Zhijie Wang , Jianjun Zhang
Targeted therapy has ushered in a new era of precision medicine for non-small cell lung cancer (NSCLC). Currently, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) stand as the recommended first-line therapy for advanced NSCLC harboring sensitive EGFR mutations. Nevertheless, most patients inevitably confront the challenge of drug resistance. This phenomenon arises not solely from intrinsic alterations within cancer cells but also from the intricate dynamics of the tumor microenvironment and the complex interactions that occur between cancer cells and their immediate surroundings. This review consolidates the current knowledge regarding EGFR-TKI resistance mechanisms, with a specific emphasis on unraveling the role played by the tumor microenvironment. In addition, the review delineates strategic approaches to surmount TKI resistance, thereby enriching the understanding of the interplay between therapeutic agents and the intricate milieu surrounding cancer cells.
靶向治疗开创了非小细胞肺癌(NSCLC)精准医疗的新时代。目前,表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKIs)是治疗携带敏感EGFR突变的晚期NSCLC的推荐一线疗法。然而,大多数患者不可避免地要面对耐药性的挑战。这种现象不仅源于癌细胞的内在改变,还源于肿瘤微环境的复杂动态以及癌细胞与其周围环境之间的复杂相互作用。本综述整合了目前有关表皮生长因子受体-TKI耐药机制的知识,尤其侧重于揭示肿瘤微环境所扮演的角色。此外,综述还阐述了克服 TKI 抗药性的策略方法,从而丰富了人们对治疗药物与癌细胞周围复杂环境之间相互作用的理解。
{"title":"Overcoming EGFR-TKI resistance by targeting the tumor microenvironment","authors":"Jinsong Zhang ,&nbsp;Natalie Vokes ,&nbsp;Man Li ,&nbsp;Jiachen Xu ,&nbsp;Hua Bai ,&nbsp;Jie Wang ,&nbsp;Zhijie Wang ,&nbsp;Jianjun Zhang","doi":"10.1016/j.pccm.2024.08.002","DOIUrl":"10.1016/j.pccm.2024.08.002","url":null,"abstract":"<div><div>Targeted therapy has ushered in a new era of precision medicine for non-small cell lung cancer (NSCLC). Currently, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) stand as the recommended first-line therapy for advanced NSCLC harboring sensitive <em>EGFR</em> mutations. Nevertheless, most patients inevitably confront the challenge of drug resistance. This phenomenon arises not solely from intrinsic alterations within cancer cells but also from the intricate dynamics of the tumor microenvironment and the complex interactions that occur between cancer cells and their immediate surroundings. This review consolidates the current knowledge regarding EGFR-TKI resistance mechanisms, with a specific emphasis on unraveling the role played by the tumor microenvironment. In addition, the review delineates strategic approaches to surmount TKI resistance, thereby enriching the understanding of the interplay between therapeutic agents and the intricate milieu surrounding cancer cells.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 151-161"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interventional pulmonology for chronic inflammatory airway diseases 慢性气道炎症性疾病的介入肺科治疗
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.08.001
Han Yang , Si Chen , Jiayuan Sun , Felix J.F. Herth
Chronic inflammatory airway diseases, such as chronic bronchitis, chronic obstructive pulmonary disease, emphysema, and bronchial asthma, pose significant healthcare challenges. Interventional treatments offer promise as valuable complements to the optimal medical therapy recommended by the Global Initiative for Chronic Obstructive Lung Disease guideline and the Global Initiative for Asthma guideline. By directly accessing the airways, these minimally invasive procedures enable precise interventions. They encompass a wide range of techniques including bronchial thermoplasty and targeted lung denervation for both chronic obstructive pulmonary disease and severe asthma, bronchoscopic lung volume reduction (including the use of endobronchial valves, coils, and bronchoscopic thermal vapor ablation), airway bypass and peripheral stent placement for emphysema, bronchial rheoplasty and spray cryotherapy for chronic bronchitis, and other emerging methods. These interventional treatments aim to improve patients’ symptoms by reducing lung volume, alleviating hyperinflation, eliminating vagal innervation, disrupting hyperplastic goblet cells and thus reducing excessive mucus secretion, and weakening submucosal smooth muscles. This review highlights the potential advantages of interventional treatments for chronic inflammatory airway diseases and discusses relevant techniques tailored to specific disease subtypes. The overall aim is to assist interventional pulmonologists in selecting the most appropriate techniques for individual patients.
慢性炎症性气道疾病,如慢性支气管炎、慢性阻塞性肺病、肺气肿和支气管哮喘,给医疗保健带来了巨大挑战。慢性阻塞性肺病全球倡议指南》和《哮喘全球倡议指南》建议采用最佳药物疗法,而介入治疗则是这一疗法的重要补充。通过直接进入气道,这些微创手术可以实现精确干预。它们涵盖了多种技术,包括用于慢性阻塞性肺病和严重哮喘的支气管热成形术和靶向肺去势术、支气管镜肺容积缩小术(包括使用支气管内瓣膜、线圈和支气管镜热蒸汽消融术)、用于肺气肿的气道分流术和外周支架置入术、用于慢性支气管炎的支气管流变成形术和喷雾冷冻疗法,以及其他新兴方法。这些介入治疗方法旨在通过减少肺容量、缓解过度充气、消除迷走神经支配、破坏增生的小泡细胞从而减少粘液的过度分泌以及削弱粘膜下平滑肌来改善患者的症状。本综述强调了慢性气道炎症性疾病介入治疗的潜在优势,并讨论了针对特定疾病亚型的相关技术。总体目标是帮助介入肺科医生为患者选择最合适的技术。
{"title":"Interventional pulmonology for chronic inflammatory airway diseases","authors":"Han Yang ,&nbsp;Si Chen ,&nbsp;Jiayuan Sun ,&nbsp;Felix J.F. Herth","doi":"10.1016/j.pccm.2024.08.001","DOIUrl":"10.1016/j.pccm.2024.08.001","url":null,"abstract":"<div><div>Chronic inflammatory airway diseases, such as chronic bronchitis, chronic obstructive pulmonary disease, emphysema, and bronchial asthma, pose significant healthcare challenges. Interventional treatments offer promise as valuable complements to the optimal medical therapy recommended by the Global Initiative for Chronic Obstructive Lung Disease guideline and the Global Initiative for Asthma guideline. By directly accessing the airways, these minimally invasive procedures enable precise interventions. They encompass a wide range of techniques including bronchial thermoplasty and targeted lung denervation for both chronic obstructive pulmonary disease and severe asthma, bronchoscopic lung volume reduction (including the use of endobronchial valves, coils, and bronchoscopic thermal vapor ablation), airway bypass and peripheral stent placement for emphysema, bronchial rheoplasty and spray cryotherapy for chronic bronchitis, and other emerging methods. These interventional treatments aim to improve patients’ symptoms by reducing lung volume, alleviating hyperinflation, eliminating vagal innervation, disrupting hyperplastic goblet cells and thus reducing excessive mucus secretion, and weakening submucosal smooth muscles. This review highlights the potential advantages of interventional treatments for chronic inflammatory airway diseases and discusses relevant techniques tailored to specific disease subtypes. The overall aim is to assist interventional pulmonologists in selecting the most appropriate techniques for individual patients.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 171-181"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns and trends in asthma incidence rates in main Asian and Western countries and their prediction to 2030 主要亚洲国家和西方国家哮喘发病率的模式和趋势以及对 2030 年的预测
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.08.004
Yang Zheng , Lei Lan , Gan Lu , Ya-dong Gao

Background

The urbanization and industrialization of East and Southeast Asia in decades past has significantly altered living environment and lifestyles, which may have complicated effects on the burden of asthma. We aim to examine the patterns and trends of asthma incidence rates in six major East and Southeast Asian countries as well as five major Western countries, and predict the numbers of new cases attributed to various factors.

Methods

Data on annual asthma incident cases and corresponding population by age group were drawn from 6 major selected East and Southeast Asian countries available in the Global Burden of Disease database, including China, Japan, Korea, Singapore, Philippines, and Thailand. We also collected data of five major high-income Western countries for comparative purposes. Two separate Bayesian age–period–cohort models, representing pre-COVID (model 1) and post-COVID (model 2) scenarios, were constructed to predict the asthma incidence until 2030.

Results

In model 1, the age-standardized incidence rate of asthma will be the highest in the US (1970.07 per 100,000, 95% confidence interval [CI] 533.05–4455.03), while the lowest incidence rate will be found in Singapore (296.72 per 100,000, 95% CI 135.16–899.55) in 2030. Between 1990 and 2030, the incidence of asthma is projected to increase in China and Thailand, with average annual percentages changes (AAPC) ranging from 0.70% to 1.80%. The remaining four Asian countries show a declining trend, with AAPC ranging from -0.51% to -2.00%. In model 2, the US is estimated to have the highest age-standardized incidence rate (902.71 per 100,000, 95% CI 375.44–2277.24), while Korea will have the lowest incidence rate (176.46 per 100,000, 95% CI 58.77–512.09) in 2030. A decrease in asthma incidence was observed in all countries with the overall AAPC ranging from -3.42% to -0.42%. Notably, a turning point was found around 2020, after which the incidence rates dropped significantly.

Conclusions

Pandemic-related factors may temporarily lower the incidence of asthma. The expected increasing asthma incidence in pre-COVID scenario (model 1) should still warrant attention from public health practitioners and call for efforts to reduce the burden of asthma.
背景过去几十年来,东亚和东南亚的城市化和工业化极大地改变了生活环境和生活方式,这可能对哮喘的负担产生复杂的影响。我们旨在研究东亚和东南亚 6 个主要国家以及西方 5 个主要国家的哮喘发病率的模式和趋势,并预测各种因素导致的新发病例数。方法 我们从全球疾病负担数据库(Global Burden of Disease database)中选取了 6 个主要的东亚和东南亚国家,包括中国、日本、韩国、新加坡、菲律宾和泰国,这些国家每年的哮喘发病病例和相应年龄组的人口数据。我们还收集了 5 个主要高收入西方国家的数据,以进行比较。我们分别建立了代表 COVID 前(模型 1)和 COVID 后(模型 2)情景的两个贝叶斯年龄-时期-队列模型,以预测 2030 年前的哮喘发病率。结果在模型 1 中,2030 年美国的年龄标准化哮喘发病率最高(每 10 万人 1970.07 例,95% 置信区间 [CI] 533.05-4455.03),而新加坡的发病率最低(每 10 万人 296.72 例,95% 置信区间 135.16-899.55)。从 1990 年到 2030 年,预计中国和泰国的哮喘发病率将上升,年均百分比变化(AAPC)从 0.70% 到 1.80% 不等。其余四个亚洲国家的发病率呈下降趋势,年均百分比变化从-0.51%到-2.00%不等。在模型 2 中,预计 2030 年美国的年龄标准化发病率最高(902.71/100,000,95% CI 375.44-2277.24),而韩国的发病率最低(176.46/100,000,95% CI 58.77-512.09)。所有国家的哮喘发病率都有所下降,总体 AAPC 从-3.42%到-0.42%不等。值得注意的是,2020 年前后出现了一个转折点,此后发病率显著下降。与大流行相关的因素可能会暂时降低哮喘的发病率,但在前 COVID 情景下(模型 1)哮喘发病率的预期增长仍应引起公共卫生工作者的注意,并呼吁努力减轻哮喘的负担。
{"title":"Patterns and trends in asthma incidence rates in main Asian and Western countries and their prediction to 2030","authors":"Yang Zheng ,&nbsp;Lei Lan ,&nbsp;Gan Lu ,&nbsp;Ya-dong Gao","doi":"10.1016/j.pccm.2024.08.004","DOIUrl":"10.1016/j.pccm.2024.08.004","url":null,"abstract":"<div><h3>Background</h3><div>The urbanization and industrialization of East and Southeast Asia in decades past has significantly altered living environment and lifestyles, which may have complicated effects on the burden of asthma. We aim to examine the patterns and trends of asthma incidence rates in six major East and Southeast Asian countries as well as five major Western countries, and predict the numbers of new cases attributed to various factors.</div></div><div><h3>Methods</h3><div>Data on annual asthma incident cases and corresponding population by age group were drawn from 6 major selected East and Southeast Asian countries available in the Global Burden of Disease database, including China, Japan, Korea, Singapore, Philippines, and Thailand. We also collected data of five major high-income Western countries for comparative purposes. Two separate Bayesian age–period–cohort models, representing pre-COVID (model 1) and post-COVID (model 2) scenarios, were constructed to predict the asthma incidence until 2030.</div></div><div><h3>Results</h3><div>In model 1, the age-standardized incidence rate of asthma will be the highest in the US (1970.07 per 100,000, 95% confidence interval [CI] 533.05–4455.03), while the lowest incidence rate will be found in Singapore (296.72 per 100,000, 95% CI 135.16–899.55) in 2030. Between 1990 and 2030, the incidence of asthma is projected to increase in China and Thailand, with average annual percentages changes (AAPC) ranging from 0.70% to 1.80%. The remaining four Asian countries show a declining trend, with AAPC ranging from -0.51% to -2.00%. In model 2, the US is estimated to have the highest age-standardized incidence rate (902.71 per 100,000, 95% CI 375.44–2277.24), while Korea will have the lowest incidence rate (176.46 per 100,000, 95% CI 58.77–512.09) in 2030. A decrease in asthma incidence was observed in all countries with the overall AAPC ranging from -3.42% to -0.42%. Notably, a turning point was found around 2020, after which the incidence rates dropped significantly.</div></div><div><h3>Conclusions</h3><div>Pandemic-related factors may temporarily lower the incidence of asthma. The expected increasing asthma incidence in pre-COVID scenario (model 1) should still warrant attention from public health practitioners and call for efforts to reduce the burden of asthma.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 188-196"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guide for Authors 作者指南
Pub Date : 2024-09-01 DOI: 10.1016/S2772-5588(24)00080-X
{"title":"Guide for Authors","authors":"","doi":"10.1016/S2772-5588(24)00080-X","DOIUrl":"10.1016/S2772-5588(24)00080-X","url":null,"abstract":"","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 200-210"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding myofibroblast origin in the fibrotic lung 了解纤维化肺中肌成纤维细胞的起源
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.08.003
Mahsa Zabihi , Mahtab Shahriari Felordi , Arun Lingampally , Saverio Bellusci , Xuran Chu , Elie El Agha
Idiopathic pulmonary fibrosis (IPF) is characterized by accumulation of myofibroblasts (MYFs) and extracellular matrix components, which leads to severe distortion and scarring of the gas exchange units of the lung, the alveoli, and ultimately respiratory failure. Fibrosis-associated MYFs are therefore widely regarded as the culprits that compromise the architectural makeup of the lung in fibrotic disease. During the past decade, the cellular source of MYFs has been intensely investigated. The rationale for such studies is that identifying the origin of these cells might help identify novel therapeutic targets and candidates to treat IPF patients. Recent advances in basic and translational research employing lineage tracing and multi-omics approaches have helped address the identity of MYF precursors, highlight the underlying heterogeneity, and to a less extent investigate MYF fate during fibrosis resolution. In this review, we discuss the current understanding of such important aspects of MYF biology as well as recent developments in the treatment of IPF.
特发性肺纤维化(IPF)的特点是肌成纤维细胞(MYFs)和细胞外基质成分的积累,这会导致肺部气体交换单元--肺泡--严重变形和瘢痕形成,最终导致呼吸衰竭。因此,纤维化相关的 MYFs 被广泛认为是破坏纤维化疾病中肺部结构组成的罪魁祸首。在过去的十年中,人们对 MYFs 的细胞来源进行了深入研究。进行此类研究的理由是,确定这些细胞的来源可能有助于确定治疗 IPF 患者的新治疗靶点和候选者。最近,基础研究和转化研究取得了进展,采用了系谱追踪和多组学方法,有助于确定 MYF 前体的身份,突出潜在的异质性,并在较小程度上研究纤维化缓解过程中 MYF 的命运。在这篇综述中,我们将讨论目前对 MYF 生物学这些重要方面的理解以及治疗 IPF 的最新进展。
{"title":"Understanding myofibroblast origin in the fibrotic lung","authors":"Mahsa Zabihi ,&nbsp;Mahtab Shahriari Felordi ,&nbsp;Arun Lingampally ,&nbsp;Saverio Bellusci ,&nbsp;Xuran Chu ,&nbsp;Elie El Agha","doi":"10.1016/j.pccm.2024.08.003","DOIUrl":"10.1016/j.pccm.2024.08.003","url":null,"abstract":"<div><div>Idiopathic pulmonary fibrosis (IPF) is characterized by accumulation of myofibroblasts (MYFs) and extracellular matrix components, which leads to severe distortion and scarring of the gas exchange units of the lung, the alveoli, and ultimately respiratory failure. Fibrosis-associated MYFs are therefore widely regarded as the culprits that compromise the architectural makeup of the lung in fibrotic disease. During the past decade, the cellular source of MYFs has been intensely investigated. The rationale for such studies is that identifying the origin of these cells might help identify novel therapeutic targets and candidates to treat IPF patients. Recent advances in basic and translational research employing lineage tracing and multi-omics approaches have helped address the identity of MYF precursors, highlight the underlying heterogeneity, and to a less extent investigate MYF fate during fibrosis resolution. In this review, we discuss the current understanding of such important aspects of MYF biology as well as recent developments in the treatment of IPF.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 142-150"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development 揭示慢性阻塞性肺疾病的肺衰老机制:开发治疗药物的理想靶点
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.08.007
Justine V. Devulder
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by airflow limitation and changes in airway structures that can lead to chronic bronchitis, small airway diseases, and emphysema. COPD is the 3rd leading cause of death worldwide and despite current research, there are no curative disease treatments for COPD. As the prevalence of COPD is higher in people over 60 years old than in younger age groups, COPD is considered a condition of accelerated lung aging. Natural lung aging is associated with molecular, cellular, and physiological changes that cause alteration in lung structure, in lung function and regeneration, and decreased immune system response that could lead to lung disease like COPD. Mechanisms of accelerated lung aging are complex and composed by increased oxidative stress induced by exposure to cigarette smoke, by chronic inflammatory processes, and increased number of senescent cells within the airways. Cellular senescence is the cessation of cell division after a finite number of proliferation cycles or in response to cell stressors, such as oxidative stress. Senescent cells show activation of the cell cycle regulators p21CIP1 (cyclin-dependent kinase inhibitor-1), p16INK4 (cyclin-dependent kinase inhibitor-2A), and p53 (cellular tumor antigen p53) that lead to cell cycle arrest. Senescent cells exhibit a change in their phenotype and their metabolic activity, along with the production of proinflammatory proteins collectively known as senescence-associated secretory phenotype (SASP). This review aims to describe recent developments in our understanding of aging mechanisms and how the acceleration of lung aging participates in COPD pathophysiology and comorbidities. Understanding and targeting aging mechanisms may result in the development of new therapeutics that could be effective for COPD and also for other age-related diseases.
慢性阻塞性肺疾病(COPD)是一种慢性肺部炎症性疾病,以气流受限和气道结构改变为特征,可导致慢性支气管炎、小气道疾病和肺气肿。慢性阻塞性肺病是全球第三大死亡原因,尽管目前的研究还没有治愈慢性阻塞性肺病的方法。由于慢性阻塞性肺病在 60 岁以上人群中的发病率高于年轻群体,因此慢性阻塞性肺病被认为是一种加速肺衰老的疾病。肺的自然衰老与分子、细胞和生理变化有关,这些变化会导致肺结构、肺功能和肺再生的改变,以及免疫系统反应的下降,从而引发慢性阻塞性肺病等肺部疾病。肺部加速衰老的机制非常复杂,主要是由于暴露于香烟烟雾中导致氧化应激增加、慢性炎症过程以及气道内衰老细胞数量增加。细胞衰老是指细胞在经过一定数量的增殖周期后停止分裂,或对氧化应激等细胞应激源做出反应。衰老细胞会激活细胞周期调节因子 p21CIP1(细胞周期蛋白依赖性激酶抑制剂-1)、p16INK4(细胞周期蛋白依赖性激酶抑制剂-2A)和 p53(细胞肿瘤抗原 p53),导致细胞周期停止。衰老细胞的表型和代谢活动发生变化,并产生促炎蛋白,统称为衰老相关分泌表型(SASP)。本综述旨在描述我们对衰老机制以及肺衰老加速如何参与慢性阻塞性肺疾病病理生理学和合并症的认识的最新进展。了解衰老机制并将其作为靶点,可能会开发出对慢性阻塞性肺病和其他老年相关疾病有效的新疗法。
{"title":"Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development","authors":"Justine V. Devulder","doi":"10.1016/j.pccm.2024.08.007","DOIUrl":"10.1016/j.pccm.2024.08.007","url":null,"abstract":"<div><div>Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by airflow limitation and changes in airway structures that can lead to chronic bronchitis, small airway diseases, and emphysema. COPD is the 3<sup>rd</sup> leading cause of death worldwide and despite current research, there are no curative disease treatments for COPD. As the prevalence of COPD is higher in people over 60 years old than in younger age groups, COPD is considered a condition of accelerated lung aging. Natural lung aging is associated with molecular, cellular, and physiological changes that cause alteration in lung structure, in lung function and regeneration, and decreased immune system response that could lead to lung disease like COPD. Mechanisms of accelerated lung aging are complex and composed by increased oxidative stress induced by exposure to cigarette smoke, by chronic inflammatory processes, and increased number of senescent cells within the airways. Cellular senescence is the cessation of cell division after a finite number of proliferation cycles or in response to cell stressors, such as oxidative stress. Senescent cells show activation of the cell cycle regulators p21<sup>CIP1</sup> (cyclin-dependent kinase inhibitor-1), p16<sup>INK4</sup> (cyclin-dependent kinase inhibitor-2A), and p53 (cellular tumor antigen p53) that lead to cell cycle arrest. Senescent cells exhibit a change in their phenotype and their metabolic activity, along with the production of proinflammatory proteins collectively known as senescence-associated secretory phenotype (SASP). This review aims to describe recent developments in our understanding of aging mechanisms and how the acceleration of lung aging participates in COPD pathophysiology and comorbidities. Understanding and targeting aging mechanisms may result in the development of new therapeutics that could be effective for COPD and also for other age-related diseases.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 133-141"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burden of RSV among inpatients with lower respiratory tract infection under 5 years of age: A 10-year retrospective study in Southwest China from 2009 to 2019 5岁以下下呼吸道感染住院患者中RSV的负担:2009-2019年中国西南地区一项为期10年的回顾性研究
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.08.006
Taoyu Li , Heping Fang , Xiangyu Liu , Yu Deng , Na Zang , Jun Xie , Xiaohong Xie , Zhengxiu Luo , Jian Luo , Yulin Liu , Zhou Fu , Luo Ren , Enmei Liu

Objectives

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI). However, few comprehensive descriptions of the disease burden, medical resource utilization (MRU), and costs of RSV are available for China. This study aimed to provide the basis for the development of RSV prevention strategies by analyzing the burden of RSV among inpatients with lower respiratory tract infection under 5 years of age.

Methods

We conducted a retrospective hospital-based study from June 2009 to May 2019 in Chongqing. Inpatients with LRTI were tested for eight viruses. We analyzed the RSV disease burden, MRU, and direct hospitalization costs by using non-parametric Mann‒Whitney U test, Chi-squared test or Fisher's exact test and logistic regression.

Results

A total of 6991 children under 5 years of age with LRTI were included in this study. The overall RSV-positive rate was 34.5% (2410/6991). Prior to admission, 81.9% (1973/2410) of these RSV-positive cases were otherwise healthy. Compared with children aged 24–59 months, the odds ratio (OR) and 95% confidence interval (CI) for RSV infection were 2.509 (2.139–2.945), 1.882 (1.549–2.222), and 1.479 (1.240–1.765) for those aged 1–5 months, 6–11 months, and 12–23 months, respectively. The proportions of patients treated with invasive ventilation and continuous positive airway pressure (CPAP) were significantly higher among RSV-positive cases (1.1% [27/2410] and 3.9% [93/2410]) than RSV-negative cases (0.9% [43/4581] and 2.7% [124/4581]) (P = 0.023). Compared with RSV-negative cases, RSV-positive cases had significantly longer hospital length of stay (6 [5, 8] days vs. 6 [5, 8] days, P < 0.001) and higher hospitalization costs (963.0 [757.9, 1298.5] USD vs. 935.6 [719.7, 1296.3] USD, P = 0.022).

Conclusions

Most RSV infections occurred during early childhood and among individuals in the otherwise healthy group. Younger age was associated with a higher RSV-positive rate. Effective prevention measures are needed in the earliest stages to reduce the RSV burden.
目的呼吸道合胞病毒(RSV)是下呼吸道感染(LRTI)的主要病因。然而,中国很少有关于 RSV 的疾病负担、医疗资源利用率(MRU)和成本的全面描述。本研究旨在通过分析 5 岁以下下呼吸道感染住院患者的 RSV 负担,为制定 RSV 预防策略提供依据。住院下呼吸道感染患者接受了八种病毒的检测。我们使用非参数曼-惠特尼U检验、卡方检验或费雪精确检验和逻辑回归分析了RSV疾病负担、MRU和直接住院费用。RSV 阳性率为 34.5%(2410/6991)。入院前,81.9%(1973/2410)的 RSV 阳性病例身体健康。与 24-59 个月的儿童相比,1-5 个月、6-11 个月和 12-23 个月的儿童感染 RSV 的几率比(OR)和 95% 置信区间(CI)分别为 2.509(2.139-2.945)、1.882(1.549-2.222)和 1.479(1.240-1.765)。在 RSV 阳性病例中,接受有创通气和持续气道正压(CPAP)治疗的患者比例(1.1% [27/2410] 和 3.9% [93/2410])明显高于 RSV 阴性病例(0.9% [43/4581] 和 2.7% [124/4581])(P = 0.023)。与 RSV 阴性病例相比,RSV 阳性病例的住院时间明显更长(6 [5, 8] 天 vs. 6 [5, 8] 天,P < 0.001),住院费用更高(963.0 [757.9, 1298.5] 美元 vs. 935.6 [719.7, 1296.3] 美元,P = 0.022)。年龄越小,RSV 阳性率越高。需要在早期阶段采取有效的预防措施,以减少 RSV 的负担。
{"title":"Burden of RSV among inpatients with lower respiratory tract infection under 5 years of age: A 10-year retrospective study in Southwest China from 2009 to 2019","authors":"Taoyu Li ,&nbsp;Heping Fang ,&nbsp;Xiangyu Liu ,&nbsp;Yu Deng ,&nbsp;Na Zang ,&nbsp;Jun Xie ,&nbsp;Xiaohong Xie ,&nbsp;Zhengxiu Luo ,&nbsp;Jian Luo ,&nbsp;Yulin Liu ,&nbsp;Zhou Fu ,&nbsp;Luo Ren ,&nbsp;Enmei Liu","doi":"10.1016/j.pccm.2024.08.006","DOIUrl":"10.1016/j.pccm.2024.08.006","url":null,"abstract":"<div><h3>Objectives</h3><div>Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI). However, few comprehensive descriptions of the disease burden, medical resource utilization (MRU), and costs of RSV are available for China. This study aimed to provide the basis for the development of RSV prevention strategies by analyzing the burden of RSV among inpatients with lower respiratory tract infection under 5 years of age.</div></div><div><h3>Methods</h3><div>We conducted a retrospective hospital-based study from June 2009 to May 2019 in Chongqing. Inpatients with LRTI were tested for eight viruses. We analyzed the RSV disease burden, MRU, and direct hospitalization costs by using non-parametric Mann‒Whitney <em>U</em> test, Chi-squared test or Fisher's exact test and logistic regression.</div></div><div><h3>Results</h3><div>A total of 6991 children under 5 years of age with LRTI were included in this study. The overall RSV-positive rate was 34.5% (2410/6991). Prior to admission, 81.9% (1973/2410) of these RSV-positive cases were otherwise healthy. Compared with children aged 24–59 months, the odds ratio (OR) and 95% confidence interval (CI) for RSV infection were 2.509 (2.139–2.945), 1.882 (1.549–2.222), and 1.479 (1.240–1.765) for those aged 1–5 months, 6–11 months, and 12–23 months, respectively. The proportions of patients treated with invasive ventilation and continuous positive airway pressure (CPAP) were significantly higher among RSV-positive cases (1.1% [27/2410] and 3.9% [93/2410]) than RSV-negative cases (0.9% [43/4581] and 2.7% [124/4581]) (<em>P</em> = 0.023). Compared with RSV-negative cases, RSV-positive cases had significantly longer hospital length of stay (6 [5, 8] days <em>vs.</em> 6 [5, 8] days, <em>P</em> &lt; 0.001) and higher hospitalization costs (963.0 [757.9, 1298.5] USD <em>vs.</em> 935.6 [719.7, 1296.3] USD, <em>P</em> = 0.022).</div></div><div><h3>Conclusions</h3><div>Most RSV infections occurred during early childhood and among individuals in the otherwise healthy group. Younger age was associated with a higher RSV-positive rate. Effective prevention measures are needed in the earliest stages to reduce the RSV burden.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 182-187"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening for viruses in lung adenocarcinoma in China 中国肺腺癌的病毒筛查
Pub Date : 2024-09-01 DOI: 10.1016/j.pccm.2024.05.001
Zhuxing Chen , Peng Liang , Haoxiang Xu , Shengli Yang , Jilong Liu , Shifu Chen , Ran Zhong , Akira Sugimoto , Wenhua Liang , Jianxing He , Tomoya Kawaguchi
{"title":"Screening for viruses in lung adenocarcinoma in China","authors":"Zhuxing Chen ,&nbsp;Peng Liang ,&nbsp;Haoxiang Xu ,&nbsp;Shengli Yang ,&nbsp;Jilong Liu ,&nbsp;Shifu Chen ,&nbsp;Ran Zhong ,&nbsp;Akira Sugimoto ,&nbsp;Wenhua Liang ,&nbsp;Jianxing He ,&nbsp;Tomoya Kawaguchi","doi":"10.1016/j.pccm.2024.05.001","DOIUrl":"10.1016/j.pccm.2024.05.001","url":null,"abstract":"","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 3","pages":"Pages 197-199"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of pulmonary endothelial barrier dysfunction in acute lung injury and acute respiratory distress syndrome 急性肺损伤和急性呼吸窘迫综合征的肺内皮屏障功能障碍机制
Pub Date : 2024-06-01 DOI: 10.1016/j.pccm.2024.04.002
Yunchao Su , Rudolf Lucas , David J.R. Fulton , Alexander D. Verin

Endothelial cells (ECs) form a semi-permeable barrier between the interior space of blood vessels and the underlying tissues. Pulmonary endothelial barrier integrity is maintained through coordinated cellular processes involving receptors, signaling molecules, junctional complexes, and protein-regulated cytoskeletal reorganization. In acute lung injury (ALI) or its more severe form acute respiratory distress syndrome (ARDS), the loss of endothelial barrier integrity secondary to endothelial dysfunction caused by severe pulmonary inflammation and/or infection leads to pulmonary edema and hypoxemia. Pro-inflammatory agonists such as histamine, thrombin, bradykinin, interleukin 1β, tumor necrosis factor α, vascular endothelial growth factor, angiopoietin-2, and platelet-activating factor, as well as bacterial toxins and reactive oxygen species, cause dynamic changes in cytoskeletal structure, adherens junction disorganization, and detachment of vascular endothelial cadherin (VE-cadherin) from the actin cytoskeleton, leading to an increase in endothelial permeability. Endothelial interactions with leukocytes, platelets, and coagulation enhance the inflammatory response. Moreover, inflammatory infiltration and the associated generation of pro-inflammatory cytokines during infection cause EC death, resulting in further compromise of the structural integrity of lung endothelial barrier. Despite the use of potent antibiotics and aggressive intensive care support, the mortality of ALI is still high, because the mechanisms of pulmonary EC barrier disruption are not fully understood. In this review, we summarized recent advances in the studies of endothelial cytoskeletal reorganization, inter-endothelial junctions, endothelial inflammation, EC death, and endothelial repair in ALI and ARDS, intending to shed some light on the potential diagnostic and therapeutic targets in the clinical management of the disease.

内皮细胞(EC)在血管内部空间和下层组织之间形成了一道半透性屏障。肺内皮屏障的完整性是通过涉及受体、信号分子、连接复合体和蛋白质调控的细胞骨架重组的协调细胞过程来维持的。在急性肺损伤(ALI)或更严重的急性呼吸窘迫综合征(ARDS)中,由于严重的肺部炎症和/或感染导致内皮功能障碍,继发内皮屏障完整性丧失,从而导致肺水肿和低氧血症。组胺、凝血酶、缓激肽、白细胞介素 1β、肿瘤坏死因子 α、血管内皮生长因子、血管生成素-2 和血小板活化因子等促炎激动剂,以及细菌毒素和活性氧、引起细胞骨架结构的动态变化、粘连接头的紊乱和血管内皮粘连蛋白(VE-cadherin)与肌动蛋白细胞骨架的分离,从而导致内皮通透性增加。内皮与白细胞、血小板和凝血的相互作用增强了炎症反应。此外,感染期间的炎症浸润和相关的促炎症细胞因子的产生会导致内皮细胞死亡,从而进一步损害肺内皮屏障的结构完整性。尽管使用了强效抗生素和积极的重症监护支持,ALI 的死亡率仍然很高,因为肺内皮屏障破坏的机制尚未完全清楚。在这篇综述中,我们总结了 ALI 和 ARDS 中内皮细胞骨架重组、内皮间连接、内皮炎症、内皮细胞死亡和内皮修复的最新研究进展,旨在为临床治疗该疾病的潜在诊断和治疗靶点提供一些启示。
{"title":"Mechanisms of pulmonary endothelial barrier dysfunction in acute lung injury and acute respiratory distress syndrome","authors":"Yunchao Su ,&nbsp;Rudolf Lucas ,&nbsp;David J.R. Fulton ,&nbsp;Alexander D. Verin","doi":"10.1016/j.pccm.2024.04.002","DOIUrl":"10.1016/j.pccm.2024.04.002","url":null,"abstract":"<div><p>Endothelial cells (ECs) form a semi-permeable barrier between the interior space of blood vessels and the underlying tissues. Pulmonary endothelial barrier integrity is maintained through coordinated cellular processes involving receptors, signaling molecules, junctional complexes, and protein-regulated cytoskeletal reorganization. In acute lung injury (ALI) or its more severe form acute respiratory distress syndrome (ARDS), the loss of endothelial barrier integrity secondary to endothelial dysfunction caused by severe pulmonary inflammation and/or infection leads to pulmonary edema and hypoxemia. Pro-inflammatory agonists such as histamine, thrombin, bradykinin, interleukin 1β, tumor necrosis factor α, vascular endothelial growth factor, angiopoietin-2, and platelet-activating factor, as well as bacterial toxins and reactive oxygen species, cause dynamic changes in cytoskeletal structure, adherens junction disorganization, and detachment of vascular endothelial cadherin (VE-cadherin) from the actin cytoskeleton, leading to an increase in endothelial permeability. Endothelial interactions with leukocytes, platelets, and coagulation enhance the inflammatory response. Moreover, inflammatory infiltration and the associated generation of pro-inflammatory cytokines during infection cause EC death, resulting in further compromise of the structural integrity of lung endothelial barrier. Despite the use of potent antibiotics and aggressive intensive care support, the mortality of ALI is still high, because the mechanisms of pulmonary EC barrier disruption are not fully understood. In this review, we summarized recent advances in the studies of endothelial cytoskeletal reorganization, inter-endothelial junctions, endothelial inflammation, EC death, and endothelial repair in ALI and ARDS, intending to shed some light on the potential diagnostic and therapeutic targets in the clinical management of the disease.</p></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 2","pages":"Pages 80-87"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772558824000239/pdfft?md5=802c146601b1c651c521e1e7335e741b&pid=1-s2.0-S2772558824000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141390171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of ratios of visceral fat area/subcutaneous fat area and muscle area/standard body weight at T12 CT level with the prognosis of acute respiratory distress syndrome T12 CT 层的内脏脂肪面积/皮下脂肪面积和肌肉面积/标准体重的比率与急性呼吸窘迫综合征预后的关系
Pub Date : 2024-06-01 DOI: 10.1016/j.pccm.2024.05.004
Hui Shen , Ying He , Fan Lu , Xiaoting Lu , Bining Yang , Yi Liu , Qiang Guo

Background

It is well-known that body composition metrics can influence the prognosis of various diseases. This study investigated how body composition metrics predict acute respiratory distress syndrome (ARDS) prognosis, focusing on the ratio of visceral fat area (VFA) to subcutaneous fat area (SFA), SFA to standard body weight (SBW), VFA to SBW, and muscle area (MA) to SBW. These metrics were assessed at the level of the twelfth thoracic vertebra (T12 computed tomography [CT] level) to determine their correlation with the outcomes of ARDS. The goal was to utilize these findings to refine and personalize treatment strategies for ARDS.

Methods

Patients with ARDS admitted to the intensive care units (ICUs) of three hospitals from January 2016 to July 2023 were enrolled in this study. Within 24 hours of ARDS onset, we obtained chest CT scans to measure subcutaneous fat, visceral fat, and muscle area at the T12 level. We then compared these ratios between survivors and non-survivors. Logistic regression was employed to identify prognostic risk factors. Receiver operating characteristic (ROC) curve analysis was utilized to determine the optimal cutoff for predictors of in-hospital mortality. Based on this cutoff, patients with ARDS were stratified. To reduce confounding factors, 1:1 propensity score matching (PSM) was applied. We conducted analyses of clinical feature and prognostic differences pre- and post-PSM between the stratified groups. Additionally, Kaplan–Meier survival curves were generated to compare the survival outcomes of these groups.

Results

Of 258 patients with ARDS, 150 survived and 108 did not. Non-survivors had a higher VFA/SFA ratio (P <0.001) and lower SFA/SBW and MA/SBW ratios (both P <0.001). Key risk factors were high VFA/SFA ratio (OR=2.081; P=0.008), age, acute physiology and chronic health evaluation (APACHE) II score, and lactate levels, while MA/SBW and albumin were protective. Patients with a VFA/SFA ratio ≥0.73 were associated with increased mortality, while those with an MA/SBW ratio >1.55 cm²/kg had lower mortality, both pre- and post-PSM (P=0.001 and P <0.001, respectively). Among 170 patients with pulmonary-origin ARDS, 87 survived and 83 did not. The non-survivor group showed a higher VFA/SFA ratio (P <0.001) and lower SFA/SBW and MA/SBW (P=0.003, P <0.001, respectively). Similar risk and protective factors were observed in this cohort. For VFA/SFA, a value above the cutoff of 1.01 predicted higher mortality, while an MA/SBW value below the cutoff of 1.48 cm²/kg was associated with increased mortality (both P <0.001 pre-/post-PSM).

Conclusions

Among all patients with ARDS, the VFA to SFA ratio, MA to SBW ratio at the T12 level, age, APACHE II score, and lactate levels emerged as independent risk factors for mortality.

背景众所周知,身体成分指标可影响各种疾病的预后。本研究调查了身体成分指标如何预测急性呼吸窘迫综合征(ARDS)的预后,重点是内脏脂肪面积(VFA)与皮下脂肪面积(SFA)的比率、SFA与标准体重(SBW)的比率、VFA与SBW的比率以及肌肉面积(MA)与SBW的比率。这些指标在第十二胸椎水平(T12 计算机断层扫描 [CT] 水平)进行评估,以确定它们与 ARDS 结果的相关性。方法本研究招募了2016年1月至2023年7月期间入住三家医院重症监护室(ICU)的ARDS患者。在 ARDS 发病 24 小时内,我们进行了胸部 CT 扫描,以测量 T12 水平的皮下脂肪、内脏脂肪和肌肉面积。然后,我们比较了幸存者和非幸存者之间的这些比率。我们采用逻辑回归来确定预后风险因素。利用接收者操作特征(ROC)曲线分析来确定院内死亡率预测因素的最佳临界值。根据这一临界值,对 ARDS 患者进行了分层。为减少混杂因素,我们采用了 1:1 倾向评分匹配法(PSM)。我们对分层组之间的临床特征和预后差异进行了分析。结果 在 258 例 ARDS 患者中,150 例存活,108 例未存活。非存活患者的 VFA/SFA 比率较高(P <0.001),SFA/SBW 和 MA/SBW 比率较低(P <0.001)。主要风险因素包括高 VFA/SFA 比率(OR=2.081;P=0.008)、年龄、急性生理学和慢性健康评估(APACHE)II 评分以及乳酸水平,而 MA/SBW 和白蛋白则具有保护作用。VFA/SFA比值≥0.73的患者死亡率增加,而MA/SBW比值为1.55 cm²/kg的患者在PSM前后的死亡率均较低(P=0.001和P<0.001)。在170名肺源性ARDS患者中,87人存活,83人死亡。未存活组的 VFA/SFA 比率较高(P <0.001),SFA/SBW 和 MA/SBW 较低(分别为 P=0.003 和 P <0.001)。在该队列中也观察到了类似的风险和保护因素。结论在所有 ARDS 患者中,VFA 与 SFA 之比、T12 水平的 MA 与 SBW 之比、年龄、APACHE II 评分和乳酸水平是导致死亡的独立风险因素。
{"title":"Association of ratios of visceral fat area/subcutaneous fat area and muscle area/standard body weight at T12 CT level with the prognosis of acute respiratory distress syndrome","authors":"Hui Shen ,&nbsp;Ying He ,&nbsp;Fan Lu ,&nbsp;Xiaoting Lu ,&nbsp;Bining Yang ,&nbsp;Yi Liu ,&nbsp;Qiang Guo","doi":"10.1016/j.pccm.2024.05.004","DOIUrl":"https://doi.org/10.1016/j.pccm.2024.05.004","url":null,"abstract":"<div><h3>Background</h3><p>It is well-known that body composition metrics can influence the prognosis of various diseases. This study investigated how body composition metrics predict acute respiratory distress syndrome (ARDS) prognosis, focusing on the ratio of visceral fat area (VFA) to subcutaneous fat area (SFA), SFA to standard body weight (SBW), VFA to SBW, and muscle area (MA) to SBW. These metrics were assessed at the level of the twelfth thoracic vertebra (T12 computed tomography [CT] level) to determine their correlation with the outcomes of ARDS. The goal was to utilize these findings to refine and personalize treatment strategies for ARDS.</p></div><div><h3>Methods</h3><p>Patients with ARDS admitted to the intensive care units (ICUs) of three hospitals from January 2016 to July 2023 were enrolled in this study. Within 24 hours of ARDS onset, we obtained chest CT scans to measure subcutaneous fat, visceral fat, and muscle area at the T12 level. We then compared these ratios between survivors and non-survivors. Logistic regression was employed to identify prognostic risk factors. Receiver operating characteristic (ROC) curve analysis was utilized to determine the optimal cutoff for predictors of in-hospital mortality. Based on this cutoff, patients with ARDS were stratified. To reduce confounding factors, 1:1 propensity score matching (PSM) was applied. We conducted analyses of clinical feature and prognostic differences pre- and post-PSM between the stratified groups. Additionally, Kaplan–Meier survival curves were generated to compare the survival outcomes of these groups.</p></div><div><h3>Results</h3><p>Of 258 patients with ARDS, 150 survived and 108 did not. Non-survivors had a higher VFA/SFA ratio (<em>P</em> &lt;0.001) and lower SFA/SBW and MA/SBW ratios (both <em>P</em> &lt;0.001). Key risk factors were high VFA/SFA ratio (OR=2.081; <em>P</em>=0.008), age, acute physiology and chronic health evaluation (APACHE) II score, and lactate levels, while MA/SBW and albumin were protective. Patients with a VFA/SFA ratio ≥0.73 were associated with increased mortality, while those with an MA/SBW ratio &gt;1.55 cm²/kg had lower mortality, both pre- and post-PSM (<em>P</em>=0.001 and <em>P</em> &lt;0.001, respectively). Among 170 patients with pulmonary-origin ARDS, 87 survived and 83 did not. The non-survivor group showed a higher VFA/SFA ratio (<em>P</em> &lt;0.001) and lower SFA/SBW and MA/SBW (<em>P</em>=0.003, <em>P</em> &lt;0.001, respectively). Similar risk and protective factors were observed in this cohort. For VFA/SFA, a value above the cutoff of 1.01 predicted higher mortality, while an MA/SBW value below the cutoff of 1.48 cm²/kg was associated with increased mortality (both <em>P</em> &lt;0.001 pre-/post-PSM).</p></div><div><h3>Conclusions</h3><p>Among all patients with ARDS, the VFA to SFA ratio, MA to SBW ratio at the T12 level, age, APACHE II score, and lactate levels emerged as independent risk factors for mortality.</p></di","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"2 2","pages":"Pages 106-118"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772558824000331/pdfft?md5=e38d7a175826b55b02d8aa8234eef2e7&pid=1-s2.0-S2772558824000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chinese medical journal pulmonary and critical care medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1